MDX 401
Alternative Names: MDX-401Latest Information Update: 08 Sep 2023
At a glance
- Originator VesiCURE Therapeutics
- Class Exosome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Digestive system disorders
Most Recent Events
- 07 Sep 2023 Early research in Digestive system disorders in China (unspecified route) (VesiCURE pipeline, September 2023)
- 18 Apr 2023 VesiCURE Therapeutics has patent protection for exosome preparation technology in China (VesiCURE pipeline, September 2023)